ALK inhibition: standard of care in
ALK
+ NSCLC
(PROFILE 1007 and PROFILE 1014)
Shaw, et al. N Engl J Med 2013 368(25): 2385–94;
Solomon, et al. N Engl J Med 2014 371(23): 2167–77
PFS in patients who received prior
chemotherapy
PFS in chemotherapy-naïve patients
3.0
7.7
0
5
10
15
20
25
PFS probability
1.0
0.8
0.6
0.4
0.2
0
Time (months)
7.0
10.9
0
5
10
15
20
35
1.0
0.8
0.6
0.4
0.2
0
HR=0.45 (0.35–0.60)
Log-rank p<0.0001
Crizotinib (n=172)
Chemotherapy (n=171)
Crizotinib (n=173)
Chemotherapy (n=174)
Time (months)
30
25
HR=0.49 (0.37–0.64)
Log-rank p<0.001
